Muscle weakness and neuromuscular junctions in aging and disease
Open Access
- 2 June 2010
- journal article
- review article
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 10 (s1) , S137-S147
Abstract
A critical issue in today's super‐aging society is the need to reduce the burden of family care while continuing to make our medical institutions supportive. A rapidly emerging, major health concern is the debilitating effect of muscle weakness and atrophy from aging, termed sarcopenia; however, the molecular basis of this condition is not well understood. Our research aim is to elucidate the molecular mechanisms of age‐related muscle atrophy and to devise new measures for preventing and treating this disability. A promising treatment for muscle atrophy is the promotion of muscle regeneration by recruiting stem cells into the targeted region. The first requirement is to understand how the motor system, which consists of muscles and motoneurons, is maintained to accomplish that goal. Recent studies in the field of neuroscience have focused on neuromuscular junctions (NMJ), which play important roles in the maintenance of both motor nerves and muscle fibers. Signaling between muscles and motoneurons at NMJ supports interactions within the motor system. To understand the mechanisms involved, we focus our research on the pathogenic processes underlying neuromuscular diseases. The well‐known autoimmune disease, myasthenia gravis (MG), serves as a model not only for tracking the pathogenesis and treatment outcomes of all autoimmune diseases, but also for understanding synaptic functions in maintaining the motor system. Here, we describe recent insights into the molecular mechanisms required for the maintenance of NMJ and the related causes of muscle atrophy. Geriatr Gerontol Int 2010; 10 (Suppl. 1): S137–S147.Keywords
This publication has 36 references indexed in Scilit:
- LRP4 Serves as a Coreceptor of AgrinNeuron, 2008
- Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSKCell, 2008
- Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junctionAnnals of Neurology, 2008
- Clinical and experimental features of MuSK antibody positive MG in JapanEuropean Journal of Neurology, 2007
- Myasthenia gravis: past, present, and futureJournal of Clinical Investigation, 2006
- The Muscle Protein Dok-7 Is Essential for Neuromuscular SynaptogenesisScience, 2006
- The synaptic muscle‐specific kinase (MuSK) complex: New partners, new functionsBioEssays, 2005
- Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravisAnnals of Neurology, 2005
- The Receptor Tyrosine Kinase MuSK Is Required for Neuromuscular Junction Formation In VivoCell, 1996
- Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine ReceptorsScience, 1973